(Q44487374)

3 December 2017

title

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers (English)

1 reference

3 December 2017

1 reference

1 reference

1 reference

Chun-Jung Lin

1

1 reference

3 December 2017

Jyh-Chin Yang

2

1 reference

3 December 2017

Yow-Shieng Uang

3

1 reference

3 December 2017

Herng-Der Chern

4

1 reference

3 December 2017

Teh-Hong Wang

5

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

23

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

711-719

1 reference

Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Impact of metronidazole resistance on the eradication of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Rabeprazole: a review of its use in acid-related gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

The Influence of Cimetidine on Basal Gastrooesophageal Sphincter Pressure, Intragastric pH, and Serum Gastrin Concentration in Normal Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

24-Hour Intragastric Acidity and Plasma Gastrin during Long-Term Treatment with Omeprazole or Ranitidine in Patients with Reflux Esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Transcatheter coil embolotherapy: a safe and effective option for major colonic haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.6.711.32177

10.1592/PHCO.23.6.711.32177

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference